Medical Researchers Find Increased Risk Of Heart Defects And Cleft Palates In Babies Born To Women Using Zofran
SUMMARY: Women with severe morning sickness who were prescribed Zofran (ondansetron) — a GlaxoSmithKline drug approved by FDA for the prevention of nausea and vomiting associated with chemotherapy and radiotherapy — have had babies born with heart-related birth defects and other congenital malformations such as cleft palate and/or cleft lip.
The most concerning medical study to date about the association of Zofran with birth defects is by a group of Danish doctors, “Ondansetron use in early pregnancy and the risk of congenital malformations – a register based nationwide cohort study”, which was first presented in 2013. From a document describing that Zofran – birth defects medical research:
We found a doubling in the prevalence of major congenital heart defects in children whose mothers redeemed a prescription of [Zofran (ondansetron)] in the first trimester of pregnancy.
An earlier medical journal article from 2011, “Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects”, indicated that Zofran use as a morning-sickness drug during pregnancy results in an increased risk of cleft palate (CP).[Read this article in full at original source]
Strictly Confidential, No Obligation